Novartis researches, develops, manufactures, and markets a range of healthcare products. The Innovative Medicines segment offers patented prescription medicines, commercializes products in the areas of oncology and rare diseases, ophthalmology, immunology and dermatology, neuroscience, respiratory, cardio-metabolic, and established medicines. The Sandoz segment provides active ingredients and finished dosage forms of pharmaceuticals in the areas of cardiovascular, central nervous system, dermatology, gastrointestinal and hormonal therapies, metabolism, oncology, ophthalmic, and respiratory. The Alcon segment offers eye care products, such as eye care devices for cataract, retinal, glaucoma, and refractive surgery, as well as contact lenses and contact lens care products, including multi-purpose and hydrogen-peroxide based solutions, rewetting drops, and daily protein removers.

Show more

Employee Rating

3.7More
TypePublic
Parent CompanyGlaxoSmithKline
HQBasel, CH
Founded1996
Size (employees)126,000 (est)+5%
Websitenovartis.com
Novartis was founded in 1996 and is headquartered in Basel, CH
Report incorrect company information

Viewing summary data as a guest

Sign up for free to see all data

Key People/Management at Novartis

Vasant Narasimhan

Vasant Narasimhan

Chief Executive Officer of Novartis
Steven Baert

Steven Baert

Head of Human Resources of Novartis
Elizabeth Barrett

Elizabeth Barrett

CEO, Novartis Oncology
Bertrand Bodson

Bertrand Bodson

Chief Digital Officer of Novartis
James Bradner

James Bradner

President, Novartis Institutes for BioMedical Research (NIBR)
Richard Francis

Richard Francis

CEO, Sandoz
Show more

Novartis Office Locations

Novartis has offices in Basel, Surrey, Bangkok, Barcelona and in 33 other locations
Basel, (HQ)
Forum 1, Novartis Campus
Núñez,
1851 Ramallo
Elsene,
108 Troonstraat
São Paulo,
90 Av. Professor Vicente Rao
Dorval,
385 Boulevard Bouchard
Chaoyang Qu,
1 Jianguomen Outer St
Show all (37)
Report incorrect company information

Novartis Financials and Metrics

Novartis Revenue

Embed Graph
View revenue for all periods
Novartis's revenue was reported to be $49.11 b in FY, 2017 which is a 1.2% increase from the previous period.
USD

Revenue (FY, 2017)

49.1b

Revenue growth (FY, 2016 - FY, 2017), %

1.2%

Gross profit (FY, 2017)

31.9b

Gross profit margin (FY, 2017), %

65%

Net income (FY, 2017)

7.7b

Cash (31-Dec-2017)

8.9b
USDFY, 2014FY, 2015FY, 2016FY, 2017

Revenue

53.6b49.4b48.5b49.1b

Revenue growth, %

(8%)(2%)1%

Cost of goods sold

17.3b17.4b17.5b17.2b

Gross profit

36.3b32.0b31.0b31.9b
USDFY, 2016FY, 2017

Cash

7.0b8.9b

Accounts Receivable

8.2b8.6b

Inventories

6.3b6.9b

Current Assets

24.9b28.2b
USDFY, 2015FY, 2016FY, 2017

Net Income

7.0b6.7b7.7b

Cash From Operating Activities

11.9b11.5b12.6b

Purchases of PP&E

(2.4b)(1.9b)(1.7b)

Cash From Investing Activities

(10.8b)(3.4b)(3.1b)
USDY, 2017

Revenue/Employee

405.5k

Financial Leverage

1.8 x
Show all financial metrics

Novartis Operating Metrics

Y, 2015Y, 2016

Major Approvals (US, EU, JP)

20 16

Patients Reached

972 m965 m

Phase III Trials Products

37 29

Projects Entering Development Pipeline

8 5
Show all operating metrics

Novartis Acquisitions / Subsidiaries

Acquired CompanyDateDeal Size
Advanced Accelerator ApplicationsOctober 30, 2017$3.90 b
AveXis$8.70 b

Novartis Revenue Breakdown

Embed Graph

Novartis revenue breakdown by business segment: 12.3% from Alcon, 20.5% from Sandoz and 67.2% from Innovative Medicines

Novartis revenue breakdown by geographic segment: 6.5% from Japan , 5.1% from France, 7.5% from Germany, 34.5% from United States and 46.5% from Other

Report incorrect company information

Novartis Online and Social Media Presence

Embed Graph
Report incorrect company information

Novartis News and Updates

Novartis to launch Adamis' EpiPen rival in U.S. next year

Novartis AG said its U.S. unit Sandoz Inc will launch Adamis Pharmaceuticals Corp's emergency allergy shots next year in the United States, at a price that is about 16 percent below that of similar rival products.

Novartis investigational BYL719 (alpelisib) plus fulvestrant consistently improved PFS in patients with PIK3CA mutated HR+/HER2- advanced breast cancer in new SOLAR-1 analyses

EAST HANOVER, N.J., Dec. 6, 2018 /PRNewswire/ -- Novartis today announced additional analysis from the global Phase III SOLAR-1 trial investigating the alpha-specific PI3K inhibitor BYL719 (alpelisib) in combination with fulvestrant in men and postmenopausal women with PIK3CA mutated...

Intellia Therapeutics and Novartis Expand Cell Therapy Collaboration to Pursue CRISPR/Cas9-based Genome Editing in Additional Stem Cell Population

– Intellia’s Right to Use Proprietary Lipid Nanoparticle Technology Extended to All Settings – Intellia Will Receive a One-time $10 Million Payment

Alzheimer’s Therapeutics 2018 Global Market Key Players – Pfizer, Inc., Merck & Co. Inc., Novartis AG, Eisai Co. Ltd., H. Lundbeck A/S, AC Immune, TauRx Pharmaceuticals Ltd. – Analysis and Forecast to 2023

WiseGuyRerports.com Presents “Global Alzheimer’s Therapeutics Market 2018 by Manufacturers, Regions, Type and Application, Forecast to 2023” New Document to its Studies Database Posted via Industry Today. Follow us on Twitter @IndustryToday

Novartis India MD to step down

Drug firm Novartis India Wednesday said its Vice Chairman and Managing Director Milan Paleja has decided to step down from company, with effect form May 31, 2019. Paleja has informed the company's board of his decision to resign as the vice chairman and managing director effective May 31, 2019 for e…

Novartis India MD Milan Paleja to step down with effect from May 31

The company's board has requested the nomination and remuneration committee to identify and recommend a suitable successor for the role
Show more
Report incorrect company information

Novartis Company Life and Culture

Report incorrect company information

Novartis Frequently Asked Questions

  • When was Novartis founded?

    Novartis was founded in 1996.

  • Who are Novartis key executives?

    Novartis's key executives are Vasant Narasimhan, Steven Baert and Elizabeth Barrett.

  • How many employees does Novartis have?

    Novartis has 126,000 employees.

  • What is Novartis revenue?

    Latest Novartis annual revenue is $49.1 b.

  • What is Novartis revenue per employee?

    Latest Novartis revenue per employee is $389.8 k.

  • Who are Novartis competitors?

    Competitors of Novartis include Merck, Pfizer and Baxalta.

  • Where is Novartis headquarters?

    Novartis headquarters is located at Forum 1, Novartis Campus, Basel.

  • Where are Novartis offices?

    Novartis has offices in Basel, Surrey, Bangkok, Barcelona and in 33 other locations.

  • How many offices does Novartis have?

    Novartis has 37 offices.